A lot of work over years has clearly gone in pre-IPO in terms of successful product development to set up for inflection points post-IPO. It really is now a short time to wait for commercialisation in Bio-tech timeframes (or for most industries for that matter) assuming no further trials are required which is how the company has positioned it. I feel a lot more eyes will be on this as each week passes, particularly as initial results on the pivotal study has been released to be followed by final results.
LTR Pharma rises 58% on fast-acting erectile dysfunction nasal spray success, page-10
Add LTP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
81.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $57.02M | |||
| Open | High | Low | Value | Volume |
| 84.5¢ | 85.0¢ | 81.0¢ | $265.3K | 320.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1293 | 81.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 84.0¢ | 2986 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| LTP (ASX) Chart |